Cargando…
Chronic Myeloid Leukemia in 2020
New insights have emerged from maturing long-term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, does not predict survival, and is of unclear relevance for trea...
Autor principal: | Hehlmann, Rüdiger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544304/ https://www.ncbi.nlm.nih.gov/pubmed/33134861 http://dx.doi.org/10.1097/HS9.0000000000000468 |
Ejemplares similares
-
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020) -
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022) -
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
por: Talpaz, M, et al.
Publicado: (2013) -
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023) -
Survival with chronic myeloid leukaemia after failing milestones
por: Lauseker, Michael, et al.
Publicado: (2023)